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Abstract 
The Target of Rapamycin (TOR) pathway is responsible for the growth and 
metabolic control of a cell, in response to nutrients and stress. This pathway, 
functioning through distinct protein complexes known as TORCs (TORC1 and 
TORC2 in yeasts and humans), is highly evolutionarily conserved. This allows 
for fission yeast, S. pombe, to serve as a model for humans in this study. 
Understanding genetic control of the TOR pathway is considered to have the 
potential to present pharmacological and dietary interventions for ageing and 
age-related diseases such as Alzheimer’s and diabetes. In this study, the highly 
conserved GATA transcription factor Gaf1, orthologue of GATA6 in humans, is 
investigated for its role in TOR by studying phenotypical and transcriptional 
differences between wild type and gaf1∆ cells with and without TOR inhibition. 
The work makes use of microfermentation experiments to determine changes in 
growth kinetics as well as microarray data to understand gene expression 
changes that might underpin these phenotypes. The results highlight the need 
for further investigation in this area by suggesting a complex interplay between 
TORC1 and TORC2 and implicating Gaf1 in both spatial and temporal aspects 
of cell growth. The results support recent findings of Gaf1 involvement in 
ncRNA expression and tRNA binding, but suggest a more complicated 
involvement with organonitrogen metabolism and nitrogen catabolite repression. 
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1 Chapter 1: Introduction 
The Target of Rapamycin (TOR) pathway serves as a regulator of cellular 
metabolism and growth with regards to cell proliferation and survival (Laplante 
and Sabatini, 2009). To this effect, TOR inhibition leads to growth inhibition and 
lifespan extension in diverse experimental systems (Rallis et al., 2013). As the 
TOR pathway is highly conserved from yeast to man, research using genetically 
tractable organisms such as Schizosaccharomyces pombe (fission yeast) are 
useful and relevant models for mammalian and human TOR signalling 
pathways, and have the capacity to offer insights on physiological mechanisms 
and disease. In humans, there is a single TOR kinase while in fission yeast 
there are two, TOR1 and TOR2. The two TOR kinases exist within two 
structurally and functionally distinct protein complexes known as TOR complex 
1 (TORC1) and TOR complex 2 (TORC2) (Loewith and Hall, 2011). TORC1 
positively regulates growth and supresses cellular responses to nitrogen stress 
in the presence of a preferred nitrogen source while TORC2 is less well defined 
and is implicated in cell survival and proliferation, DNA metabolism and damage 
(Rallis et al., 2013). The following paragraphs introduce the TOR pathway in 
metabolism, growth and disease and the relationships of the GATA transcription 
factor Gaf1 with the pathway. 
 
1.1 Discovery of TOR Kinases  
TOR was initially discovered, as its name suggests, as the target pathway for 
the drug rapamycin. Rapamycin was first isolated from the bacterium 
Streptomyces hygroscorpicus by Suren Sehgal in 1972 and identified as an 
antifungal (Vezina et al., 1975). Upon further analysis rapamycin showed 
potential as an immunosuppressive drug and gained FDA approval for this 
purpose (Blenis, 2017). Initial discovery of the TOR pathway came much later in 
the early 1990s by several methods. Initially a genetic screen for 
Saccharomyces cerevisiae mutants identified the gene encoding the cellular 
receptor for rapamycin, FKPB (FPR1) (Heitman et al., 1991a) after the same 
team had previously identified FKPB as the binding protein for rapamycin’s 
structural homologue FK-506 (Heitman et al., 1991b). While the genes were 
identified in Heitman’s 1991 screen, TOR1 and TOR2, the two TOR kinase 
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homologues more commonly referred to as the targets of Rapamycin, were not 
fully characterised until 1993 and 1994 when TOR2 was identified as a target of 
rapamycin (Kunz et al., 1993) and TOR1/2 were found to be structurally and 
functionally similar but non-identical (Helliwell et al., 1994). 
 
1.2 Evolutionary Conservation of TOR kinases and TOR 
complexes  
The importance of these characterisations can only be fully appreciated when 
viewed within the context of the conservation of TOR from yeast to man. Rather 
than the two homologues found in yeast (Shertz et al., 2010), in humans TOR 
exists as only one kinase  known as mechanistic TOR or mTOR (Laplante and 
Sabatini, 2009). The isolation of mTOR came in 1994 and marked the first 
evidence that yeast could be used as a viable model organism for TOR in 
humans. mTOR was initially identified as the FKBP-rapamycin-associated-
protein (FRAP) (Brown et al., 1994) but was referred to as mTOR after it was 
found to be an orthologue to the yeast TOR homologues (Abraham, 1998). The 
existence of mTOR prompted research which established that mTOR functions 
as in yeast within two highly conserved protein complexes termed mTORC1 
and mTORC2 as shown in figure 1 (Blenis, 2017) . 
 
Figure 1: mTORC1/2 complexes and implication in diverse cellular processes 
and rapamycin inhibition of both mTOR complexes. The figure highlights that 
the role of mTORC1 is much more clearly defined than that of mTORC2 (Blenis, 
2017) 
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In all known TOR incarnations, the targets of rapamycin, TOR kinases combine 
with other proteins to create TORC1 and TORC2 as exemplified by figures 1 
and 2. The distinction between TOR1/2 and TORC1/2 is an important one when 
understanding the finer details of the pathway.  
 
 
Figure 2: TORC1/2 in S.cerevisiae and S.pombe where functional homologues 
between the species are shown by matching shape and colour. In S.cerevisiae 
the TOR kinases are involved in the opposite TOR complexes than in S.pombe. 
(Shertz et al., 2010) 
 
The two complexes were believed to be distinct due to research suggesting 
distinct functions and different subcellular localisations (Loewith and Hall, 2011) 
however more recent studies have suggested a much more complex interplay 
between them (Gonzalez and Rallis, 2017) with functions traditionally linked to 
TORC1 being mediated by TORC2 and vice versa. 
 
1.3 Emerging functions of TORC1/2 
TORC1 and TORC2 have, for many years, been linked to very separate cellular 
functions. TORC1 has mostly been linked with temporal aspects of cell size and 
growth and TORC2 with spatial growth. As research has progressed, 
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exceptions to these assumed roles continued to emerge, until they became too 
numerous to ignore. Recently there has been an acceptance that this 
separation of complex function is too constricting for the reality of TOR’s nature 
(Gonzalez and Rallis, 2017). Some such exceptions to assumed roles are: the 
involvement of TORC1 in the actin cytoskeleton (Aronova et al., 2007) and the 
involvement of TORC2 in the timing of cell division in fission yeast (Gonzalez 
and Rallis, 2017).  
To investigate these emerging roles of each complex individually, mutant strains 
can be produced where either TORC1 or TORC2 is no longer functional. For 
TORC2 the kinase itself, TOR1, can be removed by disruption or deletion of the 
tor1 gene. In respect to TORC1, TOR2 is an essential gene and disruption or 
deletion of this gene does not yield viable cells (Weisman and Choder, 2001). 
This means that TORC1 needs to be functionally disrupted by deletion of 
another TORC1 component gene such as tco89 (Nishida and Silver, 2012).  
 
1.4 TOR in Disease 
TOR inhibition has been implicated in human disease since before it was even 
defined, with the use of Rapamycin and FK506 as immunosuppressant drugs 
(Blenis, 2017). More recently TOR has been of interest in cancer research, 
mTOR has been shown to be involved in multiple cancers and dysregulation of 
TOR has been implicated in familial cancer syndromes (Beauchamp and 
Platanias, 2013). TORC1/2 inhibition has been shown to decrease the survival 
of some triple negative breast cancer (TNBC) cells in vitro and in vivo, but some 
subsets of cancer cell, such as cancer stem cells, (CSCs) are resistant to this 
leading to interest into this resistance mechanism as a drug target (Bhola et al., 
2016).  
From a wider perspective TOR is heavily implicated in several diseases, 
especially those related to ageing. It has suggested involvement in diabetes, 
Alzheimer’s, and hepatic steatosis to name a few (Dazert and Hall, 2011). 
Given the global role of TOR within the cell, it follows that impacts of its 
dysregulation would be widespread. Arguably, some of the most interesting 
research is the involvement of mTOR in neurodegenerative diseases. Here its 
involvement is due to TOR’s role in autophagy which can be used to clear 
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accumulated misfolded proteins, a common pathology among these diseases. 
Rapamycin has been utilised in some trials to use this as a treatment target 
(Dazert and Hall, 2011). This research is particularly encouraging as it presents 
an overarching approach for a few diseases that doesn’t require further 
knowledge of the poorly understood mechanisms which cause them. However, 
it does reinforce how widespread the negative implications of TOR 
dysregulation could be. The conservation of TOR from yeast to man, and its 
direct implications on a plethora of diseases, opens the door to research into 
TOR as a drug target using diverse approaches and models. 
 
1.5 TOR Inhibition 
mTOR’s existence in two protein complexes results in interesting effects during 
inhibition by rapamycin. The two complexes, mTORC1 and mTORC2, are 
differently affected by rapamycin treatment with mTORC1 inhibition occurring 
immediately and mTORC2 inhibition occurring only after prolonged treatment 
with the drug (Schreiber et al., 2015). The two mTOR complexes are not only 
structurally different from one another, they also have distinct differences in 
their downstream functions. mTORC1 is associated with the control of anabolic 
and catabolic processes in response to nutrient availability (Johnson et al., 
2013) and is much better understood than mTORC2, but it is believed that both 
could potentially affect healthy lifespan and ageing. This makes rapamycin an 
interesting potential drug as it could be used to affect mTORC1 alone or both 
mTORC1 and mTORC2. 
As TOR’s name suggests, rapamycin and its analogues or ‘rapalogs’ were the 
first inhibitors of the pathway/kinase to be used. They have long been 
considered a key candidate for the pharmacological intervention of ageing, with 
evidence showing that rapamycin increases the lifespan and health-span in 
mouse models having been successfully reproduced (Johnson and Kaeberlein, 
2016). In fission yeast, rapamycin inhibition of TOR is aided by the addition of 
caffeine (Rallis et al., 2013). Caffeine itself is a TORC1 inhibitor (Wanke et al., 
2008) and the combinational treatment with caffeine and rapamycin has a 
greater effect than the individual treatments (Rallis et al., 2013). Rapalogs hold 
an advantage over rapamycin itself as a treatment option, as they can be 
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developed to have more favourable pharmacological kinetics and specificity, 
and provide an opportunity for intellectual property which can be advantageous 
to the drug development industry (Xie et al., 2016).  
Increasing research into the success of mTOR inhibition led to not only the 
synthesis of rapalogs but also the synthesis of other, potentially more effective, 
mTOR inhibitors. Developed by AstraZeneca, the ATP-competitive mTOR 
inhibitors Torin1 (Thoreen et al., 2009) and subsequent Torin2 (Liu et al., 2013), 
are two such examples. These drugs, can inhibit both mTORC1 and mTORC2 
through the direct inhibition of the mTOR kinase (Xie et al., 2016). Torin1 has 
been used in a few settings to demonstrate anti-ageing properties. In 2015, 
Torin1 was shown to be more potent than rapamycin when inhibiting senescent 
morphology in human cells suggesting that these processes may rely on 
rapamycin insensitive components of TOR and presenting the drug potential of 
this class of mTOR inhibitors (Leontieva and Blagosklonny, 2016, Leontieva et 
al., 2015) . Very recently, dietary introduction of Torin1 has been shown to 
increase lifespan in Drosophila melanogaster without reducing fertility (Mason et 
al., 2018) showing potential for this drug to increase lifespan without reducing 
life quality. 
 
1.6 Gaf1 and TOR 
Much of the research into TOR itself is now focussed on using diverse genetic 
approaches. This presents further understanding of TOR and identifies targets 
for its control. Gaf1 is a GATA transcription factor, of 91.78 kDa in size, involved 
in the TOR pathway in fission yeast. It has been shown to be evolutionarily 
conserved with a known orthologue in humans, GATA6 (PomBase). GATA6 is a 
zinc finger domain containing, highly conserved GATA transcription factor 
(Suzuki et al., 1996) with known homologues in both mice and rats (HUGO 
Gene Nomenclature Committee). 
TORC1 has been shown to positively regulate the phosphorylation of Gaf1 
causing it to remain in the cytoplasm. When the cell encounters nitrogen stress 
TORC1 is inhibited and Gaf1 is dephosphorylated by PP2A-like phosphatase 
Ppe1. This allows it to enter the nucleus where it positively regulates isp7 and 
negatively regulates ste11 (Laor et al., 2015).  
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Figure 3: TORC1 negative regulation of Gaf1 localisation. TORC1 inhibits the 
dephosphorylation of Gaf1 causing it to remain in the cytoplasm. When the cell 
encounters nitrogen stress Gaf1 is dephosphorylated and enters the nucleus  
where it positively stimulates isp7 which in turn stimulates TORC1. (Laor et al., 
2015) 
The gene isp7 encodes for the oxygenase Isp7 which controls amino acid 
uptake by regulating the transcription of amino acid permeases. In response to 
nitrogen stress Gaf1 is no longer inhibited by TORC1 and isp7 is upregulated, 
allowing amino acid uptake to remain the same (Laor et al., 2014). The ste11 
gene codes for the transcription factor Ste11 responsible for positively 
regulating genes required for the initiation of meiosis. ste11Δ mutants have 
been shown to be completely defective in mating and sporulation whereas the 
overexpression of ste11 leads to sexual reproduction, even in stress conditions 
(Kim et al., 2012). This suggests that Gaf1 is responsible for the decrease in 
sexual reproduction during nitrogen stress.  
Currently, knowledge of TOR is making rapid strides from many different 
angles, quite possibly due to research spurred on by new interest in TOR as a 
drug target. The roles of Gaf1, as it stands, are only very partially understood, 
but the recent relevant discoveries create an interesting niche in understanding 
TOR-related nutrient and stress cellular responses. In addition, research on 
TOR has focused on the upstream players regulating its complexes and its 
direct kinase targets. Nevertheless, understanding of factors affecting TOR-
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dependent transcriptional regulation has been limited. Early data from 
microarray analyses and ChiP-seq indicate that Gaf1 mediates transcriptional 
effects downstream of TOR related to metabolism, cellular growth and ageing 
(Rallis unpublished data-personal communication). 
The aim of the present research is to understand the functions of Gaf1 in TOR-
related signalling and cellular events. with regards to specific involvement in 
TORC1/2 by cellular growth and transcriptome analysis upon TOR inhibition. 
The work makes use of the differences in inhibition between caffeine and 
rapamycin and Torin1, and spatial and temporal growth measures to enrich 
knowledge of TORC1/2 involvement. Developing a deeper understanding of 
these cellular processes could have far-reaching, knock on effects to 
pharmacological and dietary interventions for ageing and age-related diseases.  
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2 Chapter 2: Materials and Methods 
2.1 Materials 
2.1.1 Fission yeast strains 
Table 1: Table of fission yeast strains and strain names used in thesis text 
Name used in text Strain name 
Wild type (wt) 972h- 
gaf1∆ gaf1Δ::kanMX6 h- 
tco89∆ tco89::kanMX6 h+ 
tor1∆ tor1::kanMX6 h+ 
 
2.1.2 Media 
Table 2: Details of media, stressors and antibiotics 
Material Details 
YES broth/agar Formedium YES Broth 
For solid media 16g/l agar was added 
Minimal broth Formedium EMM broth without nitrogen  
NH4Cl added 
Torin1 Tocris, Cat. No. 4247 
Caffeine  Sigma Cat. No. C0750-500G 
Rapamycin LC laboratories Cat. No. R-5000 
Arginine Sigma Cat. No. A5006-100G 
clonNAT 
(nourseothricin) 
Werner Bioagents Cat. No. 5 
G418 (Geneticin) Thermofisher Cat. No. 11811023 
 
2.1.3 Primers 
Primers were designed using Pombe PCR Primer Programs from Bahler Lab 
Resources (BählerLab) and ordered from Eurofins (EurofinsGenomics, 2019).  
Description Sequence 
MX4/6cass up 5′GACATGGAGGCCCAGAATAC3′ 
MX4/6cass down 5′TGGATGGCGGCGTTAGTATC3′ 
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Gaf1 deletion 
forward 
5’ATTTCATTCGTTTATTTTTTGTTTCGGTTTTTTATT 
CGGAAACTTCCCTTTTTCTTTCTTATCCACATTTCAAG
CTGGCTCGGATCCCCGGGTTAATTAA3' 
Gaf1 deletion 
reverse 
5’TGCACACGTAAGCCTCTTGCTCATACAATTAATCGA
CTTTTCCGACAAGAAAAAAATTCAAGTCGAAAATATA
CTATCTAGAATTCGAGCTCGTTTAAAC3’ 
 
2.2 Methods 
2.2.1 Library Screening 
The Bioneer fission yeast library version 5 (Bioneer, 2010) was grown on YES 
agar at 32˚C and 10uM Torin1 YES agar plates were prepared. The library was 
spotted onto Torin1 agar plates using a Singer ROTOR machine and incubated 
at 32˚C for four days. Plates were photographed and processed into gridded 
images using the R package Gitter (Wagih and Parts, 2014) for computational 
comparison of colony size. The list of mutants with a colony size ratio of >3 and 
<100 was used for gene ontology analysis using AnGeLi (BählerLab, 2015) 
online software. GO biological processes which showed a greater than twofold 
change from the background frequency were used for analysis. The online PInt 
protein prediction tool (BählerLab) was used to predict proteins interacting with 
Gaf1 and these proteins were then compared to the list of resistant genes to 
identify future targets for research.  
 
2.2.2 Microfermentation 
Microfermentation was carried out using the m2p labs Biolector to read biomass 
over a 48hour time course. 20ml YES precultures were grown overnight at 32˚C 
to OD600~0.2 and then 1.5ml of culture was transferred to each flower plate 
well. The cultures were treated with stressors once in the plate and the 
microfermentation began immediately following this. Analysis was conducted 
using the BioLection program, the R package grofit, and in-house R scripts for 
normalisation.  
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2.2.3 Cell Size Microscopy 
A wild type YES culture was grown overnight at 32˚C to OD600=0.2 and split 
into two. One culture was then treated with 20nM Torin1. Untreated and treated 
cells were then stained with calcuofluor and septated cell lengths of 50 cells at 
each timepoint were calculated using Volocity Program. Quantitative statistical 
analysis of cell length data was performed using prism (GraphPadSoftware, 
2018). Turkey’s multiple comparisons test was chosen for statistical analysis to 
compare the mean of all timepoints to all others.  
 
2.2.4 Microarray Analysis 
Microarrays were carried out using YES wt and gaf1Δ cell cultures grown to 
OD600= 0.5 and each of these replicated and treated with 10mM 
caffeine/100ng/ml rapamycin or 20nM Torin1 for 1 hour. The twelve cultures 
used in the microarrays are shown in the table below: 
Table 3: Details of cultures used in microarray experiment 
Repeat Strain Treatment 
1 Wild type None 
1 Wild type 10mM caffeine/100ng/ml rapamycin 
1 Wild type 20nM Torin1 
1 gaf1Δ None 
1 gaf1Δ 10mM caffeine/100ng/ml rapamycin 
1 gaf1Δ 20nM Torin1 
2 Wild type None 
2 Wild type 10mM caffeine/100ng/ml rapamycin 
2 Wild type 20nM Torin1 
2 gaf1Δ None 
2 gaf1Δ 10mM caffeine/100ng/ml rapamycin 
2 gaf1Δ 20nM Torin1 
 
Cells were harvested at OD 600 ~0.2 and volumes were adjusted according to 
OD. The cells were centrifuged for 2min at 2000rpm and the supernatant was 
discarded. Cell pellets were snap frozen using liquid nitrogen and stored at 
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70˚C. Cells were thawed on ice and pellets were resuspended in 1ml of DEPC 
water, spun for 10 seconds at 5000rpm and the supernatant was discarded. 
750µl of TES was used to resuspend each pellet and 750µl of acidic phenol-
chloroform (Sigma P-1944) was added, the tubes were vortexed and incubated 
at 65˚C in a heat block. Samples were incubated for 1 hour with vortexing for 10 
seconds every 10 minutes. Samples were placed on ice for 1 minute, vortexed 
for 20 seconds and then centrifuged for 15 minutes at 20,000rcf, 4˚C. 2ml 
Qiagen phase-lock tubes were pre-spun for 10 seconds and 700µl of 
chloroform:isoamyl alcohol (24:1) (Sigma C-0549) was added to each tube. 
700ul of the water phase from the samples was added to the phase-lock tubes 
and they were mixed thoroughly by inverting. They were then centrifuged for 5 
minutes at 20,000rcf, 4˚C. 2ml Eppendorf tubes were prepared for each sample 
containing 1.5ml of 100% EtOH and 50µl of 3M NaAc pH 5.2. 500µl of the 
water-phase from each sample was transferred into these. The samples were 
vortexed for 10 seconds and stored at -20˚C overnight to precipitate. 
Samples were centrifuged for 10 minutes at 20,000 rcf at room temperature and 
the supernatant was discarded. 500µl of 70%EtOH (4˚C, made with DEPC 
water) was added and the samples were spun for a further 1 minute with the 
same tube orientation. The supernatant was discarded, and the pellets were 
spun for a further 5 seconds and any remaining supernatant was removed 
before the pellets were air dried for 5 minutes at room temperature. 100µl of 
DEPC water was added to resuspend the pellet (by pipetting and 10 sec vortex) 
and the samples were incubated at 65˚C for 1 minute. RNA concentration was 
measured using a Nanodrop and volumes corrected to use 100µg of RNA for 
purification. 3 volumes of 100% EtOH was added to excess RNA sample these 
were stored at -70˚C. Purification was carried out using RNeasy mini spin 
columns (Qiagen) as per the manufacturer’s instructions and the columns were 
eluted twice with RNase-free water. The final RNA concentration was measured 
by Nanodrop and these concentrations were then adjusted to 2µg/µl. 
After RNA extraction the microarray experiment was set up to include a pool 
system to allow all microarrays to be compared to each other and a dye swap 
between repeats to account for dye bias. This is shown in figure 4.  
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Figure 4: Diagram to show process of pool and dye swap strategy for RNA 
samples used in microarray analysis experiment.  
 
Agilent 8 × 15K custom-made S.pombe expression microarrays were used, and 
hybridizations and subsequent washes performed according to the 
manufacturer’s protocols. The obtained data were scanned and extracted using 
GenePix, processed using R scripts for quality control and normalization, and 
analyzed using GeneSpring GX3 (Agilent Technologies UK Ltd, Wokingham, 
UK). Two independent biological repeats with a dye swap were performed. 
Online bioinformatics tools and R scripts were used to analyse gene lists and 
GO enrichment was performed using the AnGeLi bioinformatics tool available 
online (BählerLab, 2015). 
 
2.2.5 Production of gaf1∆::natMX6 strain from gaf1∆::kanMX6 
DNA for transformation was prepared by PCR of a plasmid containing NAT 
Gaf1 knockout construct using the primers stated below: 
MX4/6cassUP: 5′‐GACATGGAGGCCCAGAATAC‐3′ 
MX4/6cassDwn: 5′‐TGGATGGCGGCGTTAGTATC‐3′ 
PCR product DNA fragments were separated by gel electrophoresis on 1% 
agarose gels for one hour and visualised under u/v light by staining with SYBR-
Safe.  
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gaf1∆::kanMX6 strain yeast were grown overnight in EMM media to OD 0.2-0.5. 
These cultures were then centrifuged and the cells washed with sterile water 
once before being resuspended in 1ml of sterile water. The cells were then 
centrifuged again and washed in 1ml LiAc-TE, centrifuged a final time and 
resuspended in 100ul of LiAc-TE. 5ul of DNA was added to the 100ul of cells 
and this was incubated on the bench for 10 minutes. 260ul of LiAc-TE-40%PEG 
was then added and the cells were incubated at 30˚C in a shaking incubator for 
60 minutes. After the incubation 43ul of prewarmed DMSO was added and the 
cells were heat shocked for 5 minutes at 43˚C. Cells were then centrifuged, 
washed with sterile water and then resuspended in 750ul of sterile water for 
plating on three YES agar plates. Once these plates were grown at 30˚C for 
~24-48hours they were replica plated on to YES clonNAT plates for selection. 
Any transformants were streak plated on to YES G418 and YES clonNAT plates 
to check for the absence of a KAN resistance gene and the presence of a NAT 
resistance gene.  
After the above method proved unsuccessful several alterations were made to 
the methodology one by one to improve transformation efficacy. Adaptations 
tested are shown in the table below: 
Table 4: Details of method alterations 
Original Alteration 
5ul of DNA added 10ul of DNA added 
20ml of overnight culture used 40ml of overnight culture used. 
Cells plated on YES immediately Cells left in 750ul of EMM media 
overnight on the bench before YES 
plating 
Cells incubated for 60 minutes Cells incubated for 2 hours  
Cells incubated for 60 minutes Cells incubated for 3 hours  
Cells grown in EMM media Cells grown in YES media 
Cells plated on YES immediately Cells left in 750ul YES media 
overnight in the 30˚C incubator before 
YES plating  
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Cells plated on YES immediately then 
replica plated onto YES clonNAT 
agar 
Cells left in 750ul YES media 
overnight in the 30˚C incubator before 
plating directly onto YES clonNAT 
agar 
Cells plated on YES immediately then 
replica plated onto YES clonNAT 
agar 
Cells left in 10ml YES media 
overnight in in the 30˚C incubator 
before gently spinning down, removal 
of excess media and plating directly 
onto YES clonNAT agar. 
Cells incubated for 60 minutes in 
30˚C shaking incubator 
Cells incubated for 60 minutes in 
30˚C stationary incubator 
Older DNA synthesised by PCR New DNA synthesised using PCR 
PCR product used directly without 
clean-up 
PCR product cleaned up using 
QUIAGEN PCR Clean Up Kit 
 
2.2.6 Production of gaf1::natMX6 strain from Wild Type strain  
DNA for transformation was produced by PCR from a plasmid containing 
NATMX6 cassette flanked by gaf1 homology regions. The PCR product 
containing the antibiotic resistance/deletion cassette was generated using the 
primers stated below: 
Gaf1DF: 5’- ATT TCA TTC GTT TAT TTT TTG TTT CGG TTT TTT ATT CGG 
AAA CTT CCC TTT TTC TTT CTT ATC CAC ATT TCA AGC TGG CTC GGA 
TCC CCG GGT TAA TTA A- 3' 
Gaf1DR: 5’- TGC ACA CGT AAG CCT CTT GCT CAT ACA ATT AAT CGA CTT 
TTC CGA CAA GAA AAA AAT TCA AGT CGA AAA TAT ACT ATC TAG AAT 
TCG AGC TCG TTT AAA C- 3’ 
PCR product DNA fragments were separated by gel electrophoresis on 1% 
agarose gels for one hour and visualised using SYBR-Safe. 
Wild type fission yeast was grown overnight in YES media to OD 0.2-0.5. The 
cultures were then centrifuged and washed with sterile water once. Following 
centrifugation cells were resuspended in 1ml of sterile water. The cells were 
then centrifuged and washed in 1ml LiAc-TE, before being centrifuged a final 
time and then resuspended in 100ul of LiAc-TE. 5ul of DNA was added to the 
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100ul of cells and this was incubated on the bench for 10 minutes. 260ul of 
LiAc-TE-40%PEG was then added, and the cells were incubated at 30˚C in a 
static incubator for 60 minutes. After the incubation 43ul of prewarmed DMSO 
was added and the cells were heat shocked for 5 minutes at 43˚C. Cells were 
then centrifuged, washed with sterile water, and then resuspended in 750ul of 
YES and incubated at 30˚C overnight. These cells were then plated on to YES 
clonNAT plates for selection.  
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3 Chapter 3: Results  
The techniques and approaches used in this investigation were specially 
chosen to develop a well-rounded view of Gaf1 involvement in TOR in fission 
yeast from both a phenotypical and transcriptomic standpoint. A genome wide 
screen for Torin1 resistance was used to demonstrate the gaf1∆ phenotype and 
identify mutants with a similar phenotype. Growth kinetics analysis was used 
along with cell size microscopy to further develop understanding and identify 
features of this phenotype of long life in TOR inhibition. Transcriptomics in the 
form of microarrays identified some potential expression changes responsible 
for the phenotypes observed in the previous experiments.  
 
3.1 A Genome-wide screen for mutants resistant to Torin1 
A genome-wide Torin1-resistance screen using the version 5 Bioneer fission 
yeast deletion library covering 3,400 haploid deletion mutants with a 95.3% 
genome coverage (Bioneer, 2010) was performed to identify deletion mutants 
resistant to Torin1 growth inhibition. gaf1 was one of the strains identified to be 
resistant. Mutants showed differences in growth between control YES plates 
and Torin1 YES 10uM Torin1 plates (figure 5A and 5B).  Plates were 
photographed and then colonies were quantified using the Gitter software 
(Wagih and Parts, 2014). An example of the photographed plates is shown in 
figure 5A and 5B and the processed quantified images in figure 5C and 5D. 
Firstly all colonies were normalised with the median of each plate to correct for 
differential growth between plates. The size ratio between the control and 
Torin1 plate colony size was then taken for each knockout strain to generate a 
ratio. From these ratios a gene list is created including all knockout mutants 
where the colony size ratio is >3 and <100 to be used for gene ontology (GO) 
enrichment; these arbitrary cut-offs are used to reduce the influence of outliers 
in the screen data on the GO analysis.  
The results of the GO analysis which showed >twofold changed frequency to 
that of the background are shown in figure 6, a >twofold cut-off was used to 
identify the gene functions which were most disproportionately seen in the gene 
list as opposed to the background genome frequency. Figure 6 shows that most 
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of the resistant mutants are related to the endosome, vacuole and vesicular 
transport.  
This study’s Torin1 resistant knockout gene of interest, gaf1, has been shown to 
be resistant to Torin1 in previous screens (Lie et al., 2018) and was also shown 
here to be resistant with a library screen ratio of 8.79. PInt protein interaction 
analysis for Gaf1 is shown in figure 6. Here, line thickness denotes the 
confidence of the prediction and known interactions in S.cerevisiae are shown 
in red. Two genes were found to be both in the PInt predictions and as Torin1 
resistant with a colony size ratio of >3 and <100. These can be found 
highlighted in yellow in figure 7 and detailed in table 5 along with GO biological 
processes for these genes.  
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Figure 5: Example of image processing step for library screen data. Images A-D 
show the first control and Torin1 plates: (A) photograph of plate ‘Control 1-4’ (B) 
photograph of plate ‘Torin1 1-4’ (C) quantified image of plate ‘Control 1-4’ (D) 
quantified image of plate ‘Torin1 1-4’. This image processing is repeated for the 
remaining control and Torin1 library plates before quantification using the R 
package Gitter (Wagih and Parts, 2014) to produce a table of strains and colony 
size ratios.  
 
A B 
C D 
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Figure 6: GO functions shown have a >twofold changed frequency in the Torin1 
resistant gene list compared to the background genome frequency produced 
using AnGeLi (BählerLab, 2015). Endosome, vacuole and vesicle transport are 
particularly highlighted as common functions among genes resistant to Torin1 
inhibition. 
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Figure 7: Diagram of PInt protein interaction predictions for gaf1 (BählerLab) 
where line thickness represents confidence in prediction, red lines represent 
known interactions from BioGRID, and genes which also showed resistance to 
Torin1 treatment in the screen are highlighted in yellow.   
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Table 5: Genes identified by both the Torin1 library screen and the PInt 
Interaction prediction for gaf1. PInt Interaction prediction tool uses two machine 
learning algorithms, Support Vector Machine (SVM) and Random Forest (RF). 
Using the two combined returns fewer but more confident predictions 
(BählerLab).  
Gene ID Gene 
name 
Library 
screen ratio 
SVM 
Score 
RF 
Score 
GO Biological 
process 
SPAC16E8.01 shd1 
 
3.389796882 
 
0.783875 0.612 Actin cytoskeleton 
organisation and 
vesicle mediated 
transport. 
SPBC3B8.02 php5 3.055288347 0.873156 0.702 Regulation of 
transcription by 
RNA polymerase 
II. 
  
Of the two genes found to be in both the library screen gene list and also the 
PInt prediction gene list. php5 was also identified as resistant to Torin1 in a 
previous screen (Lie et al., 2018). The GO enrichment can be used to develop 
an understanding of which biological processes allow interaction between gaf1 
and the identified genes.  
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3.2 Growth kinetics analysis of gaf1∆ mutant using 
microfermentation 
Once gaf1∆ had been identified as resistant to Torin1 by both the previous 
published library screen (Lie et al., 2018) and the screen carried out in this 
work, a more comprehensive analysis of cellular growth changes was required. 
The library screen implicated Gaf1 in TOR signalling so microfermentation was 
used to further investigate any differences in growth kinetics as well as quantify 
the growth of gaf1∆ in the presence of Torin1.  
Microfermentation analysis and quantification of lag phase using a modified R 
script based on the grofit package (Kschischo, 2010) (figure 9B) of wild type 
and gaf1∆ strains showed that gaf1∆ has a shorter lag phase compared to wild-
type when treated with 15mM of Torin1, while the untreated cultures displayed 
identical growth kinetics and reached stationary phase simultaneously (Figure 
8). To further investigate the behaviour of wild-type and gaf1∆ cells we 
undertook experiments in which Torin1-treated cultures were supplemented 
with arginine, a TOR stimulator (Yuan et al., 2015). Addition of arginine to the 
cultures could lead to counteraction and reversion of the effects of Torin1 
inhibition.  Wild type cells showed a decrease (rescued) lag phase where gaf1∆ 
cells did not. tor1∆ and tco89∆ (tco89∆ being a core component of fission yeast 
TORC1) cells were also tested, and both showed rescued lag phases with the 
addition of arginine (figure 9). 
All Torin1 treated cultures displayed a signature decrease in biomass 
immediately and until ~hour 5. This decrease in biomass was present even in 
gaf1∆ cells and was rescued by the addition of arginine in both wild type and 
gaf1∆ cells (figure 10). Increasing concentrations of arginine caused an 
unexpected increase in lag phase length (figure 11A). This correlated directly 
with the increasing pH found by increasing concentrations of arginine (figure 
11B).  
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Figure 8: Biomass graph from BioLection showing wild type control (red), gaf1∆ 
control (blue), wild type+Torin1 15uM (green) and gaf1∆+Torin15uM (yellow). 
Both strains show increased lag phase and slower exponential phase growth 
rate when treated with Torin1. The treated wt strain has an increased lag phase 
and slower exponential growth rate than the treated gaf1∆ strain suggesting 
gaf1∆ resistance to Torin1. 
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Figure 9: A) Biomass graph from BioLection showing wild type control (red), 
gaf1∆ control (blue), wild type + Torin1 15mM (green), gaf1∆ + Torin1 15mM 
(yellow), wild type + Torin15mM and arginine (purple) and gaf1∆ + Torin 15mM 
and arginine (orange) (B) Bar graph to show changes in lag phase length for 
gaf1∆, wild type, tco89∆ and tor1∆ cells when treated with Torin 10mM, Torin 
15mM and Torin 15mM + arginine. All strains except gaf1∆ showed a rescue of 
the increased lag phase with arginine.  
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Figure 10: Biomass graph from BioLection showing arginine rescue of 
“Signature Torin1 Biomass Decrease” in both wild type and gaf1∆ strains: wild 
type and Torin1 10mM (red), gaf1∆ Torin1 10mM (blue), wild type Torin1 10mM 
and arginine (green) and gaf1∆ Torin1 10mM and arginine (yellow). 
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Figure 11: A)Biomass graph from BioLection showing increasing lag phase and 
(B) pH graph from BioLection showing increasing pH in wild type cells control 
(red), Torin1 2uM (blue), Torin1 2uM + arginine 4mM (yellow), Torin1 2uM + 
arginine 12mM (green), Torin1 2uM +arginine 16mM (purple), Torin1 2uM + 
arginine 20mM (orange). As the concentration of arginine increases, the pH 
increases and the lag phase increases.  
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Figure 12: Biomass graph from BioLection (A) wild type, (B) gaf1∆, (C) tor1∆ 
and (D) tco89∆ control (red) caffeine 10mM and rapamycin 100ng/ml (blue). 
gaf1∆ cells are seen to be more resistant to caffeine and rapamycin inhibition 
than the wild type, tor1∆ and tco89∆ strains but all strains show decreased 
growth with caffeine and rapamycin treatment.  
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Alternatively to Torin1, combined caffeine and rapamycin treatment can be used 
to inhibit TOR in fission yeast. 10mM caffeine and 10ng/ml rapamycin treatment 
of wild type, gaf1∆, tor1∆ and tco89∆ cells inhibited growth in all cases, 
increasing lag phase in all cases and decreasing overall cell density in wild 
type, tor1∆ and tco89∆. In wild type, gaf1∆ and tco89∆ strains a signature 
decrease appeared on the treated cultures immediately following exponential 
growth (figure 12). Nevertheless, as in the case of Torin1, gaf1∆ seems to be 
more resistant to caffeine/rapamycin combinational treatment compared to wild 
type cells. This is in accordance to previous results and genome wide screens 
with this drug combination(Rallis et al., 2014). 
The microfermentation results give an overview of the changes in cellular 
growth in both wild type and gaf1∆ cells with and without TOR inhibition from a 
temporal perspective. TOR controls both spatial and temporal aspects of cell 
growth (Gonzalez and Rallis, 2017), so it is necessary to investigate if Gaf1 is 
involved in only temporal or also spatial aspects of TOR control.  
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3.3 Examining Spatial Aspects of TOR inhibition using Cell 
Size Microscopy  
After collecting data on temporal aspects of cell growth we turned to 
investigating spatial aspects of cell growth. Both spatial and temporal aspects of 
cell growth have strong links to TOR control (Gonzalez and Rallis, 2017). We 
performed a time-course of Torin1 inhibition with or without arginine 
supplementation, coupled with microscopy and measurement of cell size 
changes, to record spatial downstream effects of pan-TOR inhibition.  
Cell size data collected over a 60-minute period shows that wild type cells 
treated with Torin1 decrease in size from an average of 15.2 micrometres to an 
average of 13.8 micrometres over this time frame whereas cells treated with 
both Torin1 and arginine show no significant decrease in size from the original 
size at time zero with an average size of 15.1 micrometres after 60 minutes 
(figure 13 and table 6). Statistical analysis of this data using ANOVA and 
Turkey’s multiple comparisons test in Prism (table 6) showed cells treated with 
Torin1 to be statistically significantly smaller than time zero to <99th percentile 
and statistically significantly smaller than those treated with Torin1 and arginine 
to <95th percentile. It showed no statistically significant difference in cell size 
between the time zero cells and those treated with Torin1 and arginine. Cell 
size was also shown to be statistically significant to <99th percentile between 
cells treated with Torin1 and measured at 15 minutes and those treated with 
Torin1 and measured at 60 minutes. This shows a rapid and steady decrease in 
cell size during this time period. 
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Figure 13: Box and whisker plots of wild type cell size measurements at 
different time points after the addition of 2µM Torin1 or 2µM Torin1 and 8mM 
Arginine, outliers shown as dots. Torin1 treatment without arginine reduced the 
cell size from time zero but Torin1 treatment with arginine did not. 
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Table 6: p-values for Turkey’s multiple comparisons test of cell size data 
showing p-value for each comparison and if there is a significant difference 
between them. The p-values show significant differences in cell size between 
cells treated with only Torin1 and those treated with Torin1 and arginine at both 
time points.  
COMPARISON P VALUE SIGNIFICANT? 
TIME ZERO - 15MIN TORIN1  0.0227 YES 
TIME ZERO - 60MIN TORIN1 <0.0001 YES 
TIME ZERO - 15MIN TORIN1+ARGININE 0.9221 NO 
TIME ZERO - 60MIN TORIN1+ARGININE 0.9912 NO 
15MIN TORIN1 - 60MIN TORIN1 0.0013 YES 
15MIN TORIN1+ARGININE - 60MIN 
TORIN1+ARGININE  
0.9958 NO 
15MIN TORIN1 - 15MIN TORIN1+ARGININE 0.1829 YES 
60MIN TORIN1 - 60MIN TORIN1+ARGININE <0.0001 YES 
 
 
Subsequent analyses (not part of this MRes) of gaf1 cells with Torin1 and 
arginine treatments as described above indicate that arginine can ‘rescue’ the 
Torin1-induced cell size decrease in the gaf1 mutant background as also seen 
in figure 10.  
Given that Gaf1 is a transcription factor these temporal and spatial changes in 
cell growth can be further investigated in relation to Gaf1 by gene expression 
analysis. The growth changes seen could be due to gene expression 
differences between wild type and gaf1∆ cells in normal and TOR-inhibited 
conditions.  
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3.4 Gene expression analysis of wt and gaf1∆ cells using 
microarrays 
A two-colour microarray experiment using custom made arrays (Agilent) was 
conducted in two biological repeats with a dye swap, to account for dye bias. 
Sample pools were used as reference to allow all genotypes and treatments to 
be directly comparable. Pooled samples were labelled with the opposite dye 
and used as a background comparison to all individual samples. This process 
was repeated with a dye swap for the duplicate samples and pool (figure 4). 
Duplicates were averaged and normalised before up and down regulated gene 
lists were produced by GenSpring. An example of the Lowess normalised data, 
limma and marray packages and in-house R scripts is shown in figure 14. The 
approach with pools and dye swaps is common in such experiments and has 
been successfully used in the past in numerous fission yeast studies (Rallis et 
al., 2013, Rallis et al., 2014). 
Normalised data were inserted into the Genespring program where differentially 
expressed genes were extracted using standard approaches within the 
program. Up- and down-regulated gene lists were initially compared using an 
online bioinformatics tool to create Venn diagrams, shown in figure 15.  
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Figure 14: Microarry normalisation data for wt caffeine and rapamycin 2nd 
Repeat showing raw and filtered values (grey vs orange data in the top left 
panel) as well as cut-offs and value filtering (red horizontal lines in nine left 
panels). The scripts also examine local biases on the microarray that could 
happen due to technical reasons during hybridisations (white and green panels 
with red dots on the left). 
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Figure 15: Venn diagrams to show overlap in (A) downregulation of genes in 
gaf1∆ and wild Type cells treated with caffeine and rapamycin or Torin1 (B) 
upregulation of genes in gaf1∆ and wild type cells treated with caffeine and 
rapamycin or Torin1 (C) up and downregulation of genes in gaf1∆ cells treated 
with caffeine and rapamycin or Torin1. Created using Gene Venn (Nagarajan, 
2006). 
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Figure 15 A is a Venn diagram representation of downregulated genes showing 
44 genes to be exclusively downregulated in Torin1 treatment of gaf1∆, 100 
genes less than those exclusive to the wild type strain treated with Torin1. The 
number of upregulated genes (as shown in figure 15B) were much more similar 
for these two categories but there were still less in the gaf1∆ category with 61 
as opposed to 85 genes. Figure 15C shows only a single gene overlap between 
the up and down regulated genes in the case of both the caffeine and 
rapamycin and Torin1 treatments. 
Gene lists produced by Venn diagram bioinformatics tools were then further 
analysed using a gene ontology enrichment tool, AnGeLi (BählerLab, 2015). A 
gene list of genes at least twofold downregulated in wild type cells treated with 
Torin1 but not at least twofold downregulated in wild type cells treated with 
caffeine and rapamycin was cross referenced with a gene list of genes at least 
twofold downregulated in gaf1 cells treated with Torin1 but not at least twofold 
downregulated in gaf1∆ cells treated with caffeine and rapamycin. This cross 
referencing produced a gene list of these genes found only in the wild type cells 
and a gene list of these genes found only in the gaf1∆ cells.  
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Figure 16: Bar graph to show GO enrichment percentage list frequency of 
>twofold change from background frequency on gene lists of (A) genes 
exclusively downregulated in wt treated with Torin1 and (B) genes exclusively 
downregulated in gaf1∆ treated with Torin1. Significantly more processes seem 
to be downregulated in the wt strain than the gaf1∆ strain which supports the 
hypothesis of gaf1∆ strain’s reduced response to Torin1 treatment.  
 
  
A 
B
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GO enrichment results which were at least a twofold change from the 
background frequency percentage are shown in the bar charts in figure 16. It 
shows an overlap in downregulation between wild type and gaf1∆ cells with 
regards to genes involved in translation, cytoplasmic translation, 
ribonucleoprotein complex biogenesis and ribosome biogenesis. 
Disproportionate downregulation in genes involved in formation of the 
cytoplasmic translation initiation complex and ‘de novo’ protein folding are 
shown to be exclusive to gaf1∆ cells (figure16B), while that of those involved in 
the processing and metabolic processes of ribosomal RNA and non-coding 
RNA are shown to be exclusive to wild type cells (figure16A).  
Gene lists were then produced in the same way of all genes either exclusive to 
caffeine and rapamycin treatment or found in both caffeine and rapamycin 
treatment and Torin1 treatment for both gaf1∆ and wild type cells. GO 
enrichment performed on these two lists where the list frequency showed at 
least a twofold change from the background frequency can be found in figure 
17. Notably, rRNA and ncRNA processing and metabolic processing are seen 
to be strongly downregulated in both the wild type and gaf1∆ cells.  
This process was then repeated to produce GO enrichment analysis for 
upregulated genes. 
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Figure 17: Bar graph to show GO enrichment percentage list frequency of 
>twofold change from background frequency on gene lists of (A) genes 
downregulated exclusively  in wt treated with caf/rap and overlap 
downregulation in wt treated with caf/rap and wt treated with Torin1 and (B) 
genes downregulated exclusively in gaf1∆ treated with caf/rap and overlap 
downregulation in gaf1∆ treated with caf/rap and gaf1∆ treated with Torin1. 
There is a more similar number and range of processes seen between the wt 
and gaf1∆ strain downregulation in response to treatment with caffeine and 
rapamycin than seen in response to Torin1 treatment.  
 
A 
B 
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Figure 18 (previous page): Bar graph to show GO enrichment on gene lists of 
(A) genes exclusively upregulated in wt treated with Torin1 (all GO biological 
processes shown) and (B) genes exclusively upregulated in gaf1∆ treated with 
Torin1 (GO biological processes with percentage list frequency of >twofold 
change from background frequency shown). Many more processes are seen to 
be upregulated by the gaf1∆ strain than the wt strain during the Torin1 
treatment. This supports the hypothesis of reduced downregulation in response 
to Torin1 treatment in the gaf1∆ strain.   
 
Interestingly, the list of genes upregulated in wild type but not gaf1∆ cells in 
Torin1 treatment showed only two results from GO enrichment, while neither 
were quite of a twofold change from the background frequency the results have 
been included in figure 18A as both were of a >1.9 times decrease from the 
background frequency and they were the only hits found by the screen. They 
are similar in function with both being metabolic processing of macromolecules. 
Figure 18B shows the GO enrichment for the list of genes upregulated in gaf1∆ 
but not wild type cells during Torin1 treatment. Here a wide range of biological 
processes are seen to be disproportionately represented in the gene list, most 
notably a great number of metabolic and catabolic processes are seen to be 
relatively too common in the gene list. 
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Figure 19: Bar graph to show GO enrichment percentage list frequency of 
>twofold change from background frequency on gene list of genes upregulated 
exclusively in wt treated with caf/rap and overlap downregulation in wt treated 
with caf/rap and wt treated with Torin1. May more processes are seen to be 
upregulated in the wt cells when treated with caffeine and rapamycin than when 
treated with Torin1.  
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Figure 19 shows the GO enrichment for the list of genes upregulated 
exclusively by wild type cells treated with caffeine and rapamycin and 
upregulated in wild type cells both when they are treated with caffeine and 
rapamycin and when they are treated with Torin1. In this dataset, 
organonitrogen metabolic and catabolic processes are seen to be 
disproportionately more common in the gene list than the background. The GO 
enrichment analysis of the list of genes found to be upregulated in gaf1∆ cells 
treated with caffeine and rapamycin and found to be upregulated in both gaf1∆ 
cells treated with caffeine and rapamycin or treated with Torin1 produced no 
GO Biological Process hits with more than a twofold change from the 
background frequency.  
Overall, the microarray data and subsequent GO enrichment produced large 
amounts of data to suggest the expression changes responsible for the growth 
changes seen in the gaf1∆ phenotype during TOR inhibition. The data also 
suggested downstream implications of Gaf1 deletion raising the need to 
characterise the Gaf1 interactome.  
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3.5 Production of Strain for Synthetic Genetic Arrays 
The initial goal of the project was to identify genes that might sensitise gaf1 to 
Torin1 using Synthetic Genetic Array (SGA) screening. This type of experiment 
would have produced a dataset of an undefined interactome of gaf1 and a 
Torin1 dependent interactome highlighting genes which enhance or abolish the 
Torin1-resistant phenotype of gaf1∆ cells.  
SGA analysis is a technique where a mutant of interest (query strain), in this 
case gaf1∆, is mated to the entire Bioneer fission yeast deletion library (Bioneer 
2010). The resulting double knockout colony sizes are used as a proxy to show 
if the genes have a genetic interaction and if this is positive or negative. During 
mating an integral step is to select for cells containing both knockout constructs, 
this is achieved by growth on relevant selective media. The gaf1∆ strain used in 
this study contained a kanamycin (G418) resistance gene, which is also the 
gene in the Bioneer deletion library. For this reason, a gaf1∆ strain with a 
different selection marker would be needed for selection of double mutants after 
mating.   
Transformations to produce h-gaf1∆::natMX6 strain from h-gaf1∆::kanMX6 
strain produced only colonies resistant to both clonNAT and G418. Fresh DNA 
insert was amplified by PCR and analysed by gel electrophoresis shown in 
figure 20A. The transformation of a wild type strain was attempted but did not 
produce any transformants. The DNA fragment for this was also synthesised by 
PCR and analysed by gel electrophoresis as shown in figure 20B. In both cases 
PCR product was cleaned up using a Qiagen PCR clean-up kit before use in 
the transformation protocol however this still provided no transformants. The 
plan for production of Gaf1 interactomes using SGAs will still be pursued within 
the lab but not included in this thesis. 
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Figure 20: 1% agarose gel electrophoresis of PCR product (1.45kb) visualised 
using SYBR-Safe for (A) h-gaf1∆::kanMX6 to h-gaf1∆::natMX6 transformation 
(B) wild type to h-gaf1∆::natMX6 transformation. Fragment bands are indicated 
between 1kb and 1.5kb ladder fragments by the grey arrow. 
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4 Chapter 4: Discussion  
Deletion of gaf1, coding for a GATA transcriptional regulator results in cells that 
are resistant to Torin1 growth inhibition. Mutants resistant to Torin1 are related 
to vesicle transport (figure 6), a process also identified by a previous published 
screen (Lie et al., 2018). However, to date, gaf1 has not been involved with this 
biological process. Nevertheless, the Gaf1 orthologue in budding yeast, Gat1, 
has been shown to be to be strongly connected with vacuole and vesicle 
transport (Fayyadkazan et al., 2014, Kingsbury and Cardenas, 2016). To better 
understand the underlying mechanism of the resistance of gaf1∆ to Torin1, the 
mutants found resistant in our screen were cross-referenced with predicted 
protein interactions with gaf1 (figure 7). Two genes were identified as both 
resistant to Torin1 inhibition and as predicted to physically interact with Gaf1 
protein (table 5). The gene with the strongest confidence in prediction, php5, is 
involved in regulation of transcription via RNA polymerase II. This function is 
closely related to a gaf1 function: RNA polymerase II proximal promoter 
sequence-specific DNA binding (Pombase). The other gene identified, shd1 
(cytoskeletal protein binding protein Sla1 family), codes for a protein involved in 
vesicle-mediated transport and this could present a potential way that gaf1∆ 
resistance is also vesical transport mediated. Interestingly shd1 has been 
shown to be long lived in a previous caffeine and rapamycin screen (Rallis et 
al., 2014) implicating it in TORC1 signalling. Intracellular trafficking and 
endocytosis have been found to contribute to necrotic neurodegeneration 
(Troulinaki and Tavernarakis, 2012) and therefore shd1-mediated lifespan 
extension would be a gene of interest for future ageing studies. Both php5 and 
shd1 would be genes of interest in a future synthetic genetic array experiment 
to investigate their interaction with gaf1. 
The use of a library screen is very useful as a tool to quickly identify, in genomic 
scale, genes which are particularly resistant to or sensitised by certain 
nutritional or pharmacological factors, such as Torin1; however the screen is 
very much an initial experiment and requires follow-up experiments. Some 
results of the screen can be considered unreasonable and were excluded from 
the final result list. For example, this screen identified genes which had colony 
size ratios of 212 and 232. These ratios are not necessarily inaccurate however 
it is advisable to be cautious of such extreme results as they are likely to not be 
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reproducible. As a next step it is important to establish a gene of interest’s 
Torin1 resistance by other methods to verify the library screen results. This can 
be done in several ways such as using stress spot plate experiments, 
chronological lifespan assays or microfermentation. As well as this, screens can 
be compared to previous published library screens to help establish their 
reliability. The results of this screen showed a strong similarity with the results 
from the published screen in not only identified gene hits but also GO metabolic 
processes (Lie et al., 2018). 
Spotting serial dilutions of mutant cultures on plates are a similar experiment to 
the library screen and can produce only limited data as, due to their qualitative 
nature, they are unable to provide insight into the growth curve of the cells; 
therefore, they are more appropriate for use as a quick validation method than 
an actual experimental measurement for which a quantitative method is 
preferable. For this study microfermentation, which provides quantitative growth 
aspects was preferable to lifespan assays as the data is produced much more 
quickly and therefore many more conditions could be studied in a relatively 
limited time frame. In addition, the effect of Torin1 on the chronological lifespan 
of fission yeast is an integrated part of another study within the lab and is not 
the focus of this thesis. 
Figure 8 shows that gaf1∆ cells are resistant to Torin1 inhibition compared to 
wild type cells with regards to lag phase. This confirms the resistance shown in 
the library screen and clearly shows that the difference in growth kinetics can be 
potentially explained by the decreased lag phase. Figure 8 also highlighted a 
signature decrease in biomass in response to Torin1 in both gaf1∆ and wild 
type cultures. To rescue the effects of Torin1 inhibition, arginine, a potent TOR 
stimulator (Yuan et al., 2015), was added to the cultures. This notably rescued 
the lag phase in wild type but not gaf1∆ cells; however, it rescued the signature 
decrease in biomass in both (figure 9). The same microfermentation experiment 
included tor1∆ and tco89∆ (a functional deletion mutant of a fission yeast 
TORC1 core component) and both cultures here also showed lag phase rescue 
with the addition of arginine. This suggests that potentially the arginine lag 
phase rescue effect is a Gaf1-dependent process related to Gaf1’s role in 
stimulating amino acid uptake in response to TOR inhibition via isp7 (Laor et al., 
2014).  
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To find the optimum arginine concentration for lag phase rescue in wild type a 
microfermentation experiment was set up to include a range of arginine 
concentrations. Figure 11A shows that increasing levels of arginine results in 
increasing lag phases rather than the rescue that had previously been seen. To 
identify the cause of this, pH was also measured in an identical experimental 
setup and the rapidly increasing pH shown in figure 11B correlates exactly with 
the biomass with the pH levelling and the biomass effect ending at ~10-16 
hours respectively. This led to the conclusion that while arginine can rescue 
Torin1-induced lag phase extension, when increasing arginine concentration 
increases the pH of the culture too much this effect is overridden by the effect of 
more alkaline conditions. This means that a more effective arginine treatment 
could be created by pH correcting media plus arginine in future experiments.  
Interestingly, the rescue of the signature decrease in biomass appears 
independent of the pH changes and is unlikely to have been caused by them 
since Torin1 treatment itself increases pH from the control but less so than low 
concentrations of arginine. Figure 10 shows that the Torin1-dependent 
decrease in biomass seen in both wt and gaf1∆ can be rescued by addition of 
arginine to the culture. This decrease in biomass was hypothesised to be 
caused by a reduction in cell size, supported by the data in figure 13. Here it is 
shown that, at both time points, the addition of Torin1 significantly reduced cell 
size from time zero however the addition of Torin1 and arginine did not, clearly 
showing that arginine does rescue a cell size reduction in Torin1 treatment. 
Potentially this reduction in cell size could be due to temporal aspects of the cell 
cycle alteration causing the cells to divide earlier or spatial aspects of cell 
growth such as metabolic dependent cell size in response to treatment by 
Torin1 (Gonzalez and Rallis, 2017, Rallis et al., 2013). gaf1∆ cells show the 
same signature as the wild type cells, so it can be theorised that this is also due 
to a reduction in cell size. The data suggests that lag phase rescue in response 
to arginine treatment is Gaf1 and pH dependent whereas the cell size rescue is 
Gaf1 and pH independent.  
Temporal aspects of cell growth have long been associated with TORC1 and 
spatial aspects of cell growth with TORC2, however recent research suggests a 
crossover of functions (Gonzalez and Rallis, 2017). TORC1 inhibition should 
lead to Gaf1 dephosphorylation and consequent migration into the nucleus 
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(Laor et al., 2015). In gaf1∆ cells the loss of downstream Gaf1 functions are 
believed to be the cause of Torin1 resistance so it is an interesting point for 
further research that the deletion of Gaf1 and its downstream targets have no 
effect on the signature biomass decrease potentially caused by cell size 
reduction but does affect temporal aspects such as cellular lifespan and lag 
phase.  
In this study, the biomass decrease is a feature seen in Torin1 TOR inhibition 
but not caffeine and rapamycin TOR inhibition. It is known that caffeine and 
rapamycin inhibition of TORC1 causes cell size reduction by advancing mitotic 
onset (Gonzalez and Rallis, 2017, Rallis et al., 2013). With this in mind, while 
previous literature shows that cell size can be TORC1 dependent (Rallis et al., 
2013), the biomass decrease was not seen in the caffeine and rapamycin 
results through microfermentation analysis, suggesting that further study 
surrounding the mechanism would be needed to fully determine the involvement 
of TORC1/TORC2 in this phenomenon. Figure 12 shows an unexplained 
decrease in biomass in caffeine and rapamycin treatment at ~20 hours not 
present on the controls in gaf1∆, wt and tco89∆ but not tor1∆, the functional 
knockout of TORC2. There is a potential for further study of cell size at this 
point as it is known that prolonged treatment with rapamycin causes TORC2 
inhibition. Correlating cell size microscopy data could potentially suggest that 
this response could be TORC2 mediated as well as the already known TORC1 
involvement (Rallis et al., 2013). The theory that the Torin1 dependent decrease 
in cell size could be TORC2 dependent would explain how it could be Gaf1 
independent as Gaf1 is directly dephosphorylated by TORC1 inhibition but it’s 
involvement with TORC2 is currently undefined and may be less direct.  
Gene expression analysis was performed using a custom microarray platform. 
This technique was chosen over alternatives because microarrays were already 
an established pipeline within the lab and the technique was less expensive 
than other options, such as RNA-Seq. Microarray analysis is an established and 
reliable method of expression analysis, however there are limitations; 
microarrays are not an open platform such as RNA-Seq meaning that the 
technique is restricted by the pre-chosen number of gene probes included 
within the array.  Microarrays are also affected by cross or non-specific 
hybridisation background noise. During the lowess normalisation and analysis 
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of microarrays, a statistical assumption is made that most genes show no 
change. This means that some small expression changes may not be detected 
if they are hidden by this assumption.  
Microarray analysis was used to study the expression differences between wild 
type and gaf1∆ fission yeast treated with Torin1 as well as with a combination of 
caffeine and rapamycin. These results are likely to be valid due to the dye swap 
used to eliminate dye bias and the fact that untreated and fast growing gaf1∆ 
and wild type cells showed no difference in expression (data not shown). This 
indicates that expression changes seen are likely to be due solely to the cell’s 
response to treatment.  
Microarray data was processed to produce gene lists of up and downregulated 
genes for each parameter and these lists were initially compared using Venn 
diagrams shown in figure 15. Here there are 100 more genes exclusively 
downregulated in wild type cells in response to Torin1 treatment than in gaf1∆ 
cells in response to Torin1 treatment (figure 15A) with more similar results seen 
for upregulation (figure 15B). Figure 15C showed virtually no overlap between 
upregulated and downregulated genes in the gaf1∆ samples further evidencing 
the validity of the microarray results. This initial Venn diagram analysis 
demonstrated the heavy involvement of Gaf1 in regulating genes downstream 
of TOR and the need to further analyse these gene lists to identify Gaf1-
dependent cellular functions. To do this gene ontology enrichment analysis was 
performed using the AnGeLi online bioinformatics tool.  
Downregulated genes seen only in wild type but not gaf1∆ cells in response to 
Torin1 inhibition (figure 15A and 16A) are shown to be disproportionately 
involved in a wide range of biological processes. Some downregulation is likely 
to be Gaf1 dependent. Genes involved in translation, cytoplasmic translation, 
ribonucleoprotein complex biogenesis and ribosome biogenesis are shown to 
be downregulated in both wild type and gaf1∆ cells and so are likely not to be 
gaf1-dependent processes. Genes involved in rRNA and ncRNA processing 
and metabolic process are notably downregulated exclusively in the wild type 
cells suggesting gaf1∆ dependence in these processes. Cellular amino acid 
biosynthesis and metabolic process genes are also notably downregulated 
disproportionately in wild type cells which is interesting given Gaf1’s known 
involvement in increased amino acid uptake (Laor et al., 2014). Potentially this 
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could be to accumulate amino acids within the cell without metabolising them in 
response to TOR inhibition which is naturally caused by lack of nutrient 
availability.  
Figure 16B highlights that genes involved in the formation of the cytoplasmic 
initiation complex and de novo protein folding are disproportionately present in 
the gaf1∆ Torin1 downregulated genes list. This suggests that these two 
processes are either directly or indirectly upregulated by Gaf1 or that their 
downregulation is prevented by Gaf1 in wild type cells. This data is consistent 
with the current knowledge that Gaf1 stimulates amino acid uptake during TOR 
inhibition (Laor et al., 2014) thought to be part of a process which allows Gaf1 to 
immediately compensate for TOR inhibition in a cell. In this way, Gaf1 could 
also be responsible for stimulating other cell processes necessary for survival 
such as the translation and protein synthesis involvement seen here. Genes 
involved in the regulation of cellular processes and regulation of biological 
processes are seen to be disproportionately absent from the wild type 
downregulation shown in figure 16A, supporting this hypothesis that Torin1 
treatment leads to Gaf1 dependent stimulation of cellular processes to 
compensate for TOR inhibition.  
The distinct reduction in downregulated genes in response to Torin1 inhibition in 
gaf1∆ cells, compared to wild type cells could account for gaf1∆ resistance to 
Torin1 in terms of growth. Gaf1-dependent downregulation of rRNA and ncRNA 
processing and metabolic process included ten genes directly involved with 
tRNAs, supporting current ChiIP-seq data that Gaf1 can directly regulate tRNA 
expression, following TOR inhibition (Rodriguez-Lopez, Gonzalez et al., 
unpublished). The data so far suggest that Gaf1 is directly implicated in tRNA 
regulation following stresses and thus affecting cellular recovery and growth. 
Figure 17 further develops this picture, showing rRNA and ncRNA processing 
and metabolic processes are seen to be downregulated in both wild type and 
gaf1∆ cells. Further experiments including northern analyses of tRNAs in 
Torin1-treated and untreated wt and gaf1∆ backgrounds have shown that Gaf1 
regulates tRNA expression. Additional tests are necessary to develop and 
evidence which Gaf1 mediated effects are TORC1 and TORC2 dependent as 
this study has so far only highlighted the possibility of a more complicated 
interplay between Gaf1 and the TOR complexes without defining it.  
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The GO enrichment in figure 18 shows that in wild type cells, treated with 
Torin1, upregulation of macromolecule metabolism and catabolism was 
disproportionately absent, while upregulation of metabolism and catabolism was 
disproportionately present in gaf1∆ cells, treated with Torin1. This supports the 
idea that Gaf1 is implicated in organonitrogen metabolism, namely that of amino 
acids and nucleotides. Inhibition of TOR should lead to a reduction in metabolic 
processes (Laplante and Sabatini, 2012) as seen in the wild type cells treated 
with Torin1 however the upregulation of these processes seen in the gaf1∆ cells 
treated with Torin1 suggests that Gaf1 is integral to the suppression of some 
metabolic processes during TOR inhibition.  
Figure 19 shows the GO enrichment for the list of genes upregulated 
exclusively in wild type cells treated with caffeine and rapamycin and those 
upregulated both when wild type cells are treated with caffeine and rapamycin 
or Torin1. Here we see upregulation of organonitrogen metabolic processes but 
a lack of upregulation for several other metabolic processes. Interestingly the 
list for upregulated genes in gaf1∆ cells when treated with caffeine and 
rapamycin and upregulated when treated with either caffeine/rapamycin or 
Torin1 produced no GO enrichment hits so it cannot be used as a comparison. 
However, in the Torin1 inhibition of gaf1∆ cells we see that upregulation of 
organonitrogen processes but not of other metabolic and catabolic processes 
suggesting there may be little to no change between the wild type and gaf1∆ in 
this respect. It is known that GATA transcription factors in budding yeast, 
including the Gaf1 orthologue Gat1 are involved in nitrogen catabolite 
repression sensitive gene expression control (Cooper, 2002) and recent ChIP-
seq data (Rallis, personal communication) suggests Gaf1 regulates 
organonitrogen compound genes and potentially plays a role in nitrogen 
catabolite repression, highlighting the need for further investigation in this area 
as the GO enrichment analysis in this study appears to contradict present data.  
Following on from these results that suggest a plethora of Gaf1 transcriptional 
controls and downstream effects it was deemed useful to create a picture of the 
Gaf1 genetic interactome, this was planned using synthetic genetic array (SGA) 
analysis. Here the gaf1∆ query strain would have been mated with the fission 
yeast deletion library (Bioneer Version 5, containing ~3500 mutants) producing 
data evidencing gaf1’s involvement in cellular processes and pathways. This 
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required a gaf1∆ strain with a selective marker different from the library 
knockouts to allow for double mutant selection after mating. 
To construct this strain a transformation using a natMX6 cassette was 
attempted multiple times with 12 method adaptations, however, even after fresh 
DNA was produced by PCR (figure 20A), no successful colonies were obtained. 
On two occasions a cell line resistant to both G418 and clonNAT was generated 
suggesting that the fragment had inserted itself into a different locus. For this 
reason, the cassette was amplified from the plasmid again using new primers 
for generating an independent gaf1∆ knockout directly from wild type cells 
(figure 20B) which has larger homology regions. Using this approach we 
generated much more DNA for transformations, however no transformants were 
obtained.  Due to time constraints on the MRes project it was impossible to 
continue attempts to produce the strain necessary and therefore also 
impossible to carry out the planned SGAs. Given more time adaptations to the 
methodology for the wild type knockout would have been made until the 
transformation was successful. Alternatively, a CRISPR/Cas9 approach could 
have been used to create the strain as it would likely have been successful 
however time constraints did not allow this approach. 
In conclusion, the study has evidenced Gaf1 involvement with TORC1 in line 
with current knowledge while highlighting potential for Gaf1 involvement with 
TORC2. The gaf1∆ resistance to Torin1 has been shown to be potentially 
mediated by control of rRNA and ncRNAs including tRNAs, consistent with 
current emerging data about Gaf1-dependent gene regulation. ChIP-seq 
experiments performed by the lab but not part of this thesis have confirmed 
fission yeast Gaf1 binding to all tRNAs and ncRNAs. Genes of interest in the 
mechanism of gaf1∆ resistance to TOR inhibition by Torin1 have been identified 
by PInt prediction and a Torin1 library screen presenting suggestions for further 
study. One of these genes also presents a possible candidate for gaf1∆’s Torin1 
resistance to be connected to vesicle transport which has been highlighted by 
the library screen as a major cause of Torin1 resistance.   
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